Figure 7.
Treatment assignments in the double-blind, randomized, ARBITER 2 study and its open-label follow-up study, ARBITER 3. Numbers of patients shown are those completing each phase. The duration each phase trial was 1 year; the Niaspan® daily dose was 1000 mg. Adapted with permission from Taylor AJ, Lee HJ, Sullenberger LE. 2006. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin, 22:2243-50.